ES2132411T3 - Derivados nucleosidicos carbo-aciclicos como agentes antivirasicos y antineoplasicos. - Google Patents

Derivados nucleosidicos carbo-aciclicos como agentes antivirasicos y antineoplasicos.

Info

Publication number
ES2132411T3
ES2132411T3 ES94920695T ES94920695T ES2132411T3 ES 2132411 T3 ES2132411 T3 ES 2132411T3 ES 94920695 T ES94920695 T ES 94920695T ES 94920695 T ES94920695 T ES 94920695T ES 2132411 T3 ES2132411 T3 ES 2132411T3
Authority
ES
Spain
Prior art keywords
group
hydrogen
antivirasic
aciclicos
carbo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94920695T
Other languages
English (en)
Inventor
Jeffrey S Sabol
Sai P Sunkara
Shawn C Miller
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharmaceuticals Inc
Original Assignee
Merrell Dow Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merrell Dow Pharmaceuticals Inc filed Critical Merrell Dow Pharmaceuticals Inc
Application granted granted Critical
Publication of ES2132411T3 publication Critical patent/ES2132411T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

LA PRESENTE INVENCION VA DIRIGIDA A UNA CLASE DE DERIVADOS CARBO-ACICLICOS NOVEDOSOS CON LAS FORMULAS (I) Y (II) Y SU USO COMO AGENTES ANTIVIRALES Y ANTINEOPLASTICOS, DONDE X{SUB,1} Y X{SUB,2} SON CADA UNA INDEPENDIENTEMENTE HIDROGENO, FLUOR O CLORO, R ES HIDROGENO O HIDROXIMETIL, J ES UN RADICAL DE LAS FORMULAS (A), (B) Y (C). Y{SUB,1} ES UN GRUPO CH, UN GRUPO CC1, UN GRUPO CBR, O UN GRUPO CNH{SUB,2}, Y{SUB,2} E Y{SUB,3} SON CADA UNA INDEPENDIENTEMENTE NITROGENO O UN GRUPO CH, Y{SUB,1} ES UN GRUPO CH, UN GRUPO CC1, UN GRUPO CBR O UN GRUPO CNH{SUB,2}, Y{SUB,2} E Y{SUB,3} SON CADA UNA INDEPENDIENTEMENTE NITROGENO O UN GRUPO CH, Y{SUB,4} ES HIDROGENO, ALQUIL C{SUB,1}-C{SUB,4}, ALCOXI C{SUB,1}-C{SUB,4} O HALOGENO, Y{SUB,5} ES NH{SUB,2} O ALCOXI C{SUB,1}-C{SUB,4}, Q ES NH{SUB,2}, NHOH, NHCH{SUB,3}, OH, O HIDROGENO, Y V ES HIDROGENO, HALOGENO O NH{SUB,2}; O UNA SAL FARMACEUTICAMENTE ACEPTABLE DE LOS MISMOS.
ES94920695T 1993-06-23 1994-05-31 Derivados nucleosidicos carbo-aciclicos como agentes antivirasicos y antineoplasicos. Expired - Lifetime ES2132411T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US8172793A 1993-06-23 1993-06-23

Publications (1)

Publication Number Publication Date
ES2132411T3 true ES2132411T3 (es) 1999-08-16

Family

ID=22166006

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94920695T Expired - Lifetime ES2132411T3 (es) 1993-06-23 1994-05-31 Derivados nucleosidicos carbo-aciclicos como agentes antivirasicos y antineoplasicos.

Country Status (19)

Country Link
US (1) US6017923A (es)
EP (1) EP0705264B1 (es)
JP (1) JP3468423B2 (es)
CN (1) CN1040759C (es)
AT (1) ATE178605T1 (es)
AU (1) AU679763B2 (es)
CA (1) CA2165419C (es)
DE (1) DE69417748T2 (es)
DK (1) DK0705264T3 (es)
ES (1) ES2132411T3 (es)
FI (1) FI956246A0 (es)
GR (1) GR3030003T3 (es)
HU (1) HUT73410A (es)
IL (1) IL110051A (es)
NO (1) NO955254L (es)
NZ (1) NZ268479A (es)
TW (1) TW269690B (es)
WO (1) WO1995000515A1 (es)
ZA (1) ZA944344B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2319418A1 (en) 1998-01-30 1999-08-05 Daiso Co., Ltd. Processes for preparing butanetriol derivatives

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4199575A (en) * 1978-03-27 1980-04-22 Gunther Roland E Method of treating dermatitis venenata
US4221794A (en) * 1979-06-21 1980-09-09 Newport Pharmaceuticals International, Inc. Method of imparting immunomodulating and antiviral activity
US4355032B2 (en) * 1981-05-21 1990-10-30 9-(1,3-dihydroxy-2-propoxymethyl)guanine as antiviral agent
IL73682A (en) * 1983-12-20 1991-08-16 Medivir Ab Antiviral pharmaceutical compositions containing 9-hydroxy aliphatic derivatives of guanine,some new such derivatives and process for their preparation
US4935427A (en) * 1987-12-31 1990-06-19 The United States Of America As Represented By The Department Of Health And Human Services Pyrimidine and purine 1,2-butadiene-4-ols as anti-retroviral agents
DE68922903T2 (de) * 1988-12-19 1995-11-23 Wellcome Found Antivirale Pyrimidin- und Purinverbindungen, Verfahren zu ihrer Herstellung und sie enthaltende pharmazeutische Präparate.

Also Published As

Publication number Publication date
GR3030003T3 (en) 1999-07-30
ZA944344B (en) 1995-02-15
CN1040759C (zh) 1998-11-18
JPH08512030A (ja) 1996-12-17
TW269690B (es) 1996-02-01
EP0705264B1 (en) 1999-04-07
FI956246A (fi) 1995-12-22
AU679763B2 (en) 1997-07-10
FI956246A0 (fi) 1995-12-22
HU9503707D0 (en) 1996-02-28
CA2165419A1 (en) 1994-12-24
NO955254D0 (no) 1995-12-22
IL110051A0 (en) 1994-10-07
JP3468423B2 (ja) 2003-11-17
WO1995000515A1 (en) 1995-01-05
DE69417748D1 (de) 1999-05-12
NO955254L (no) 1996-02-21
CA2165419C (en) 1999-03-02
CN1125947A (zh) 1996-07-03
US6017923A (en) 2000-01-25
NZ268479A (en) 1997-07-27
EP0705264A1 (en) 1996-04-10
DE69417748T2 (de) 1999-08-19
IL110051A (en) 2000-01-31
DK0705264T3 (da) 1999-10-18
ATE178605T1 (de) 1999-04-15
HUT73410A (en) 1996-07-29
AU7139494A (en) 1995-01-17

Similar Documents

Publication Publication Date Title
UA26427A (uk) Похідhі ксаhтиhу у вигляді суміші ізомерів або іhдивідуальhих ізомерів, що мають властивість аhтагоhіста адеhозиhу
ATE249219T1 (de) Antivirale verbindungen
YU17591A (sh) Triazolni fungicidni agensi
DE69005164D1 (de) Acryloylsubstituierte Pyrrol-Derivate.
FI810250L (fi) Foerfarande foer framstaellning av nya terapeutiskt aktiva heterocykliska foereningar
FI935517A0 (fi) Fenoxi- och fenoxialkylpiperidiner som virusmotverkande medel
AR026352A1 (es) Derivados de imidazopiridina como inhibidores de la fosfodiesterasa vii.
AR005672A1 (es) Derivados de la distamicina, proceso para prepararlos, y su utilizacion como agentes antitumorales y antivirales.
ATE135348T1 (de) Pyrimidin-4-carboxamidderivate, ihre herstellung und ihre verwendung in der therapie
ATE260279T1 (de) Naphthyridin-derivate mit cytomegalovirus inhibierender wirkung
ATE49211T1 (de) Dreizyklische oxindole als antientzuendungsmittel.
FI812804L (fi) 2-(1,4-bensodioxan-2-ylalkyl)-imidazoler anvaendbara som antidepressiva laekemedel
MX9303990A (es) Tetrazolil (fenoxi y fenoxialquil) piperidinil piridazinas como agentes antivirales.
ES2132411T3 (es) Derivados nucleosidicos carbo-aciclicos como agentes antivirasicos y antineoplasicos.
MX9203234A (es) Derivados de 5-halovinil-2-desoxiuridina y composiciones farmaceuticas que los contienen.
MX9204194A (es) Los compuestos de 1,2,4-oxadiazolil-fenoxialquilisoxazolas y su uso como agentes antivirales
AR014135A1 (es) Profarmacos de lobucavir y metodos de uso
GB2340490A (en) Diphenylacetic acid derivatives and their use as antiviral agents
ATE220058T1 (de) Neue antiarrythmische verbindungen
YU25096A (sh) Inhibicija fotodekompozicije 3-supstituisanog-2-oksindola
ES2116878B1 (es) Derivados de ciclopropilacetonitrilo, su preparacion y su aplicacion como medicamentos.
YU106191A (sh) Aminobenzodiazepini
SE8203878D0 (sv) Antiviruskomposition
ECSP982786A (es) Profarmacos de lobucavir y metodos de uso
HRP940443B1 (en) Process for the preparation of 1-nitro-2,2-diaminoethylene derivatives

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 705264

Country of ref document: ES